Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein–Barr virus entry to the central nervous system?
Version of Record online: 1 DEC 2011
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology
Clinical & Experimental Immunology
Volume 167, Issue 1, pages 1–6, January 2012
How to Cite
Meier, U.-C., Giovannoni, G., Tzartos, J. S. and Khan, G. (2012), Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein–Barr virus entry to the central nervous system?. Clinical & Experimental Immunology, 167: 1–6. doi: 10.1111/j.1365-2249.2011.04446.x
- Issue online: 1 DEC 2011
- Version of Record online: 1 DEC 2011
- Accepted manuscript online: 10 AUG 2011 06:50PM EST
- Accepted for publication 8 June 2011
- B cells;
- Epstein–Barr virus;
- multiple sclerosis
OTHER ARTICLES PUBLISHED IN THIS MINI-REVIEW SERIES ON B CELL SUBSETS IN DISEASE
Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies. Clinical and Experimental Immunology 2012, 167: 7–14. Reconstitution after haematopoietic stem cell transplantation – revelation of B cell developmental pathways and lineage phenotypes. Clinical and Experimental Immunology 2012, 167: 15–25.
The recent success of therapies directed at B cells has highlighted their potential as central players in multiple sclerosis (MS) pathogenesis. Exciting new data showed that B cell depletion led to reduced clinical and magnetic resonance imaging (MRI) evidence of disease activity. However, the mechanisms of action remain unknown, but could involve autoantibody production, antigen presentation and/or cytokine production by B cells. Another exciting line of investigation in the field of MS comes from latent infection of memory B cells by Epstein–Barr virus (EBV). These cells are hijacked as ‘Trojan horses’ and ‘smuggle’ the virus into the central nervous system (CNS). Thus, these new anti B cell treatments will also be likely to have anti-viral effects. We briefly review recent findings in the field of MS pathogenesis, and highlight promising new targets for therapeutic intervention in MS.